CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers   Watch the &#34;What This Means&#34; video here  TAMPA, Fla. and LONDON, May  28, 2026  (GLOBE

AKTX

Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor "What This Means" Segment Following ASCO Abstract Acceptance

Akari’s AKTX-101 ASCO Data Highlights KRAS Synergy; Mid-2027 FIH Milestone

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers   Watch the &amp;#34;What This Means&amp;#34; video here  TAMPA, Fla. and LONDON, May  28, 2026  (GLOBE</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Akari Therapeutics announced the ASCO-accepted abstract for AKTX-101, featuring preclinical data showing synergy with KRAS inhibitors in KRAS-mutated pancreatic cancers and reinforcing the PH1 payload’s potential. Management also reiterated a mid-2027 target to initiate a first-in-human trial, signaling a near-term catalyst that could validate the platform and attract investor interest.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>AKTX-101 ASCO abstract accepted; preclinical KRAS synergy with KRAS inhibitors in pancreatic cancer.</li><li>CEO interview notes Phase 1 first-in-human by mid-2027; validates PH1 payload platform.</li><li>Synergy potential with checkpoint inhibitors; AKTX-101 could broaden solid-tumor applicability.</li><li>IND enabling studies ongoing; near-term clinical milestones guide shareholder value.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Akari Therapeutics, Plc (AKTX)</strong>: Directly connected; ASCO abstract acceptance and mid-2027 FIH milestone weigh on AKTX valuation; PH1 payload differentiation highlighted.</li><li><strong>KRAS inhibitors (N/A)</strong>: Discussed as a combination rationale; potential strategic relevance if a partner or specific inhibitor is pursued.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Corporate Developments: Updates on ASCO-driven validation and near-term clinical milestones for AKTX-101, signaling potential pipeline advancement and investor interest.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>ASCO abstract acceptance for AKTX-101 provides near-term validation catalyst.</li><li>Preclinical KRAS synergy data strengthen AKTX-101’s combo potential.</li><li>Mid-2027 Phase 1 first-in-human timeline sets a concrete near-term milestone.</li><li>IND enabling studies ongoing; progress could influence financing needs.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>ASCO acceptance for AKTX-101 abstract announced May 28, 2026.</li><li>Preclinical data show synergy between AKTX-101 and KRAS inhibitors in pancreatic cancer models.</li><li>Company targets Phase 1 first-in-human by mid-2027 for AKTX-101.</li><li>IND enabling studies for AKTX-101 are currently underway.</li><li>AKTX-102 targets CEACAM5; PH1 payload is a spliceosome modulator.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish; expect re-rating as ASCO data and mid-2027 FIH timing materialize.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="center"><em>CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers </em></p>  <p align="center"><em>Watch the "What This Means" video </em><a href="https://www.globenewswire.com/Tracker?data=9FfC6kLvQO8Q4kSJilTCOu3cYpjST3M5rmAY5J_W_jhrqJ_xbYi13vf3W7BWvDMVltwycPig48AHhb2yk81ZBBwTZDCrlW7H-R928knJ-iI=" rel="nofollow" target="_blank"><em>here</em></a></p>  <p align="justify">TAMPA, Fla. and LONDON, May  28, 2026  (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AKTX">AKTX</a>), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that its CEO participated in a Virtual Investor "What This Means" interview focused on the Company's recently accepted abstract at the <a href="https://www.globenewswire.com/Tracker?data=jEKuySFNLvTRFVQj10wkazC_mLXb11eMrc6s9HRq6dEpn2y6-9QxYOMqz40nFVnujV7VIcRU-LDv2x5PSpa0U7nUcHlltbu4qy-JEuEzazLdLJLq8wHDKwDWirU7w52lZCc_wqKBgXGIWI6utg6kfQ==" rel="nofollow" target="_blank">2026 American Society of Clinical Oncology (ASCO) Annual Meeting</a>.</p>  <p align="justify">During the interview, Mr. Gaslightwala highlighted the significance of Akari's first ASCO abstract acceptance and discussed newly presented preclinical data demonstrating combination synergy between Akari's differentiated spliceosome-modulating ADC platform and a KRAS inhibitor in KRAS-mutated pancreatic cancer models. The data further supports the potential of Akari's proprietary PH1 payload platform to address the most difficult-to-treat cancers with significant unmet met, such as KRAS-driven tumors.</p>  <p align="justify">"The acceptance of our data at ASCO represents an important validation milestone for Akari and reinforces the growing excitement surrounding our differentiated ADC platform," said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. "We believe AKTX-101 and our novel spliceosome-modulating payload approach have the potential to redefine how difficult-to-treat KRAS-driven cancers are targeted, particularly in patient populations where current therapeutic options remain limited."</p>  <p align="justify">The discussion also explored the key findings from the accepted abstract and what management believes differentiates Akari's approach within the rapidly evolving ADC landscape, including the Company's novel RNA splicing modulation mechanism designed to enhance anti-tumor activity and broaden therapeutic applicability across multiple solid tumor indications.</p>  <p align="justify">In addition, Mr. Gaslightwala outlined several anticipated milestones investors should monitor, including continued advancement of Akari's PH1 spliceosome-modulating payload platform and the Company's targeted initiation of a Phase 1 first-in-human clinical trial by mid-2027.</p>  <p align="justify">The Virtual Investor "What This Means" segment featuring Akari Therapeutics is now available <a href="https://www.globenewswire.com/Tracker?data=9FfC6kLvQO8Q4kSJilTCOmYfM0IUCwz8fsmV_tpzlF2wio8MUsEr9yesdN0ymvr5mmy09J4G0k4UtM45zgpTLjcKeh8I-GZkWDOvIfsN--k=" rel="nofollow" target="_blank">here</a>.</p>  <p align="justify"><strong>About Akari Therapeutics </strong></p>  <p align="justify">Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has been shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari's proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.</p>  <p align="justify">For more information about the Company, please visit <a href="https://www.globenewswire.com/Tracker?data=WCjP9KsDVVreFhhAg2f0CZASdK7-s8qsRzdEUFxPXg6YOThRG_n2TpDtW0LNKEpqB9KaOmEk_ONENzIv32hCX2taKuWcfsILedGdNBJ8Y8M=" rel="nofollow" target="_blank">www.akaritx.com</a> and connect on <a href="https://www.globenewswire.com/Tracker?data=KTu-jUfvFjxJohb5F-MFsLX7_Z_ASl4gPOJA6KUue9D7Kre_Gkd1yAakYn7Hw6CLwhJNQvLrIgqIN-KETfm8nw==" rel="nofollow" target="_blank">X</a> and <a href="https://www.globenewswire.com/Tracker?data=ZvoIB1zfOAJrgIdXw-tMvng0yQWmCJPlNxncdwdlLDBRSAdEW-rQpVuK0rqTWIw7TkGnCcxRpac8gkGz95Ynx-OyawthfLVfB11nZEdM_G4=" rel="nofollow" target="_blank">LinkedIn</a>.</p>  <p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>  <p align="justify">This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "future," "opportunity" "will likely result," "target," variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and the timing of commencement of a Phase I clinical trial. These statements are based on the Company's current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company's need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company's programs or product candidates; risks related to any loss of the Company's patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company's product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company's product candidates; risks related to competition for the Company's product candidates; and the Company's ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the SEC, copies of which may be obtained from the SEC's website at <a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a>. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.</p>  <p align="justify"><strong>Investor Relations Contact </strong></p>  <p align="justify">JTC Team, LLC <br></br>Jenene Thomas <br></br>908-824-0775 <br></br><a href="https://www.globenewswire.com/Tracker?data=Z2S2VCMUeH39lckrN0x8mMUnCJh0eTbpXCorIH744GVbW5uSrIpm67fhNo1U94WNYZy4DY-fqMBbvJoO58izEg==" rel="nofollow" target="_blank">AKTX@jtcir.com</a>    </p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcyNzg3NiM3NjI0OTE0IzIwMjAyNjM="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/Y2QyYTIwMzMtZmVlMC00YTk0LTk3ZGYtNTc1MWY0MWUzODc2LTEwMzE4MzUtMjAyNi0wNS0yOC1lbg==/tiny/Akari-Therapeutics-Plc.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/8d978f50-07a9-40a3-be69-45f51ccd94d9"><img src="https://ml.globenewswire.com/media/8d978f50-07a9-40a3-be69-45f51ccd94d9/small/akari-logo-1-jpg.jpg" border="0" width="150" height="130" alt="Primary Logo"></img></a></p>

Akari Therapeutics announced the ASCO-accepted abstract for AKTX-101, featuring preclinical data showing synergy with KRAS inhibitors in KRAS-mutated pancreatic cancers and reinforcing the PH1 payload’s potential. Management also reiterated a mid-2027 target to initiate a first-in-human trial, signaling a near-term catalyst that could validate the platform and attract investor interest.

akari-therapeutics-discusses-breakthrough-potential-of-aktx-101-and-novel-spliceosome-modulating-adc-platform-in-virtual-investor-what-this-means-segment-following-asco-abstract-acceptance

Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor "What This Means" Segment Following ASCO Abstract Acceptance

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News